The incidence of neoplasms was higher in anti-RNA Pol III patients than in people that have anti-topo I or anticentromere antibodies (ACA) positivity (14
The incidence of neoplasms was higher in anti-RNA Pol III patients than in people that have anti-topo I or anticentromere antibodies (ACA) positivity (14.2% vs 6.3% and vs 6.8% respectively). malignancies, respectively. Furthermore, immune system checkpoint inhibitors useful for tumor therapy can induce immune-related undesirable events, which are more serious…